SBRT + Atezolizumab + Bevacizumab in Resectable HCC

NCT04857684 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Resectable Hepatocellular Carcinoma

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
RADIATION: Stereotactic Beam Radiation Therapy (SBRT)

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]